VT-1021
- Generic Name
- VT-1021
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Phase 2
Recruiting
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Global Coalition for Adaptive Research
- Target Recruit Count
- 1030
- Registration Number
- NCT03970447
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸St. Joseph Hospital, Orange, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Vigeo Therapeutics, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03364400
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath